Abstract
Adenovirus biology and cancer biology have progressed in a complementary fashion. For example, proteins encoded at the virus’ E1 region were found to bind to the tumor suppressor proteins p53 and pRB, and these interactions played an important role in characterizing the role of these tumor suppressors in virus-dependent and -independent transformation (1, 2). Perhaps, then, it is a natural extension of this history that human adenoviruses are now being developed as anticancer agents. Ironically, although advances in genetic engineering have permitted the development of replication-disabled adenoviruses as simple delivery vehicles for therapeutic genes (3–5), replication-competent wildtype strains were actually the first to be administered safely to patients (6). Now, nearly a half-century later, replication-competent adenoviruses are once again being studied as therapeutic agents (7–9). However, genetic engineering has now been used with the goal of maximizing tumor-selective replication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
